Clinical Trials Search

Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Thakar MD, Keyur
Sponsor: NCI
Details (Identifier #): NCT02502266
Title: Protocol NRG-GY005,A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: Mirati
Details (Identifier #): NCT02219711
Title: Mirati Therapeutics Inc., 516-001: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: Mirati
Details (Identifier #): NCT02544633
Title: Mirati 265-109 Amethyst, A Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lash MD, Bradley
Sponsor: MacroGenics
Details (Identifier #): NCT02492711
Title: MacroGenics SOPHIA, CP-MGAH22-04, A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lash MD, Bradley
Sponsor: NSABP Foundation
Details (Identifier #): NCT02664077
Title: NSABP C-13, A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients with Stage III Colon Cancer (ARGO)